David Hutton, Managing Editor, Ophthalmology Times

OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA gene, the company stated in a news release.

The goal of the grant funding from the Choroideremia Research Foundation is to support validation of functional vision assessments for patients with profound blindness.

The company stated that 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.

The Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the other arm with 75 participants that are gene agnostic.

The effort led to the creation of an artificial vitreous body for treating retinal detachment. This solution is based on a natural carbohydrate derived from algae.

Phentolamine ophthalmic solution 0.75% is a preservative-free, stable eye drop, which blocks the α1 receptor within the iris dilator muscle without affecting the ciliary muscle.

Since its U.S. launch in September 2023, more than 40,000 avacincaptad pegol intravitreal solution vials have been distributed to physician practices.

According to the company, its Virtual Eye Pro features improve visual field testing for practice and patients.

The ANX007 global pivotal program is the first to use vision preservation as a primary outcome measure in GA.

According to the company, AGTC-501 was generally safe and well-tolerated and showed improvements in visual function at the 12-month analysis. The Phase 2/3 VISTA trial for AGTC-501 in XLRP expected to begin in in the first half of 2024.

In a news release, the FDA noted these are copycat eye drop products that consumers can easily mistake for Bausch + Lomb’s Lumify brand eye drops, an over-the-counter product approved for redness relief.

The new contact lenses contain micro-sensors which monitor changes in IOP over a period of several hours, sending the data collected wirelessly so it can be analyzed by an eye care provider and a diagnosis given.

According to researchers, the strongest biomarker was achieved from a single bright flash of light to the right eye, with AI processing significantly reducing the test time.

Available information includes a new promotional toolkit for The Glaucoma Community, glaucoma patient testimonial, and medical expert interview videos.

According to Ocuphire Pharma, phase 3 startup activities are underway, and the clinical trial is expected to start in the first quarter of 2024.

Vezocolmitide is the first drug candidate based on PolyCol, Stuart Therapeutics' patented synthesized polypeptide collagen mimetic peptide platform.

iDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has received FDA approval following a new drug application (NDA) submission.

OCU410 is a modifier gene therapy product candidate being developed by Ocugen for dry AMD.

The company announced key secondary endpoints were achieved with both EYP-1901 doses. These include a more than 80% reduction in treatment burden, with nearly two-thirds of eyes supplement-free up to 6 months.

The smart contact lens is designed to offer a non-invasive solution for patients suffering from keratoconus, corneal irregularities, photophobia, and presbyopia.

Prevent Blindness is providing free geographic atrophy educational resources for patients, care partners and healthcare professionals, including a new episode of its Focus on Eye Health Expert series.

According to the company, an additional trial is required to show positive effects on the treatment of ocular symptoms in dry eye disease.

According to the companies, the merger creates a NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics’ lead assets for the treatment of presbyopia.

According to Sun Pharmaceutical Industries, the study design mirrors real-world experience with dry eye disease, including allowing use of artificial tears and measurement of CFS in all 5 corneal zones.

Patients who have signs or symptoms of an eye infection after using these products should talk to their health care provider or seek medical care immediately.

According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.

In July 2023, Harrow received certain US and Canadian commercial rights for 6 branded products from Santen.

According to a human study of older adults, grape intake improved macular pigment accumulation and downregulated harmful biomarkers.

Misusing contact lenses can be hazardous. Contact lens wearers also must take extra care when applying and removing eye cosmetics.

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.